Lincoln Pharmaceuticals Limited (NSE:LINCOLN)

Lincoln Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	224.31	57.47	50.52	69.34	138.41
Short-Term Investments	1,737	1.18	116.57	113.82	-
Trading Asset Securities	-	1,389	913.26	968.06	806.65
Cash & Short-Term Investments	1,961	1,448	1,080	1,151	945.06
Cash Growth	35.48%	34.01%	-6.16%	21.81%	103.47%
Accounts Receivable	1,664	1,618	1,363	1,159	1,133
Other Receivables	6.77	0.64	1.35	3.4	2.06
Receivables	2,024	2,011	1,604	1,490	1,333
Inventory	786.77	771.68	700.28	727.42	466.13
Prepaid Expenses	-	16.25	19.36	3.73	11.37
Other Current Assets	227.42	220.48	268.29	156.19	331.8
Total Current Assets	4,999	4,467	3,672	3,528	3,088
Property, Plant & Equipment	1,860	1,825	1,569	1,476	1,119
Long-Term Investments	0.03	0.04	0.03	0.03	1.04
Other Intangible Assets	4.4	3.26	2.95	3.83	3.98
Other Long-Term Assets	46.25	47.63	33.74	65.15	59.76
Total Assets	7,970	7,003	5,874	5,344	4,524
Accounts Payable	849.48	724.4	508.67	716.67	570.66
Accrued Expenses	-	90.06	82.92	70.14	58.49
Short-Term Debt	-	10.67	19.97	20.44	-
Current Portion of Long-Term Debt	-	-	-	-	3.75
Current Income Taxes Payable	-	0.71	8.82	42.77	31.59
Other Current Liabilities	212.68	96.93	101.08	54.85	93.91
Total Current Liabilities	1,062	922.77	721.45	904.86	758.4
Long-Term Debt	-	-	-	-	1.45
Long-Term Unearned Revenue	-	36.25	47.21	45.39	42.92
Long-Term Deferred Tax Liabilities	130.02	114.56	79.41	64.55	56.91
Other Long-Term Liabilities	61.2	-	-	-	-
Total Liabilities	1,253	1,075	849.46	1,015	859.67
Common Stock	200.3	200.3	200.3	200.3	200.3
Additional Paid-In Capital	-	646.17	646.17	646.17	646.17
Retained Earnings	-	5,182	4,279	3,580	2,916
Comprehensive Income & Other	6,516	-100.06	-100.67	-97.7	-99
Total Common Equity	6,717	5,928	5,025	4,329	3,664
Shareholders' Equity	6,717	5,928	5,025	4,329	3,664
Total Liabilities & Equity	7,970	7,003	5,874	5,344	4,524
Total Debt	-	10.67	19.97	20.44	5.2
Net Cash (Debt)	1,961	1,437	1,060	1,131	939.86
Net Cash Growth	36.49%	35.53%	-6.22%	20.31%	127.17%
Net Cash Per Share	97.92	71.75	52.94	56.46	46.92
Filing Date Shares Outstanding	20.03	20.03	20.03	20.03	20
Total Common Shares Outstanding	20.03	20.03	20.03	20.03	20
Working Capital	3,937	3,545	2,951	2,624	2,329
Book Value Per Share	335.40	295.98	250.86	216.12	183.20
Tangible Book Value	6,712	5,925	5,022	4,325	3,660
Tangible Book Value Per Share	335.18	295.82	250.72	215.93	183.00
Land	-	200.24	187.36	186.32	172.57
Buildings	-	602.21	580.66	478.61	357.92
Machinery	-	1,548	1,192	1,031	875.31
Construction In Progress	-	34.83	67.14	160.54	16.86

Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.